Implementing diffusion-weighted MRI for body imaging in prospective multicentre trials: current considerations and future perspectives.
For body imaging, diffusion-weighted MRI may be used for tumour detection, staging, prognostic information, assessing response and follow-up. Disease detection and staging involve qualitative, subjective assessment of images, whereas for prognosis, progression or response, quantitative evaluation of...
| Publicado en: | European Radiology Vol. 28; no. 3; pp. 1118 - 1132 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , |
| Formato: | research Journal Article |
| Publicado: |
Springer Nature
Mar2018
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=127990327&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 127990327 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 09387994 NPH jtl: European Radiology issn: 09387994 maglogo: N pubinfo: dt: Mar2018 vid: 28 iid: 3 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 127990327 127990327 NLM28956113 127990327 10.1007/s00330-017-4972-z NLM28956113 127990327 ppf: 1118 ppct: 14 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Implementing diffusion-weighted MRI for body imaging in prospective multicentre trials: current considerations and future perspectives. aug: au: deSouza, N. M. Winfield, J. M. Waterton, J. C. Weller, A. Papoutsaki, M.-V. Doran, S. J. Collins, D. J. Fournier, L. Sullivan, D. Chenevert, T. Jackson, A. Boss, M. Trattnig, S. Liu, Y. affil: CRUK Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, SM2 5PT, Surrey, UK sug: subj: Magnetic Resonance Imaging Methods Neoplasms Software Magnetic Resonance Imaging Standards Prognosis Prospective Studies Reproducibility of Results Human Disease Progression Research Subjects Multicenter Studies Quality Assurance Ferrans and Powers Quality of Life Index Scales ab: For body imaging, diffusion-weighted MRI may be used for tumour detection, staging, prognostic information, assessing response and follow-up. Disease detection and staging involve qualitative, subjective assessment of images, whereas for prognosis, progression or response, quantitative evaluation of the apparent diffusion coefficient (ADC) is required. Validation and qualification of ADC in multicentre trials involves examination of i) technical performance to determine biomarker bias and reproducibility and ii) biological performance to interrogate a specific aspect of biology or to forecast outcome. Unfortunately, the variety of acquisition and analysis methodologies employed at different centres make ADC values non-comparable between them. This invalidates implementation in multicentre trials and limits utility of ADC as a biomarker. This article reviews the factors contributing to ADC variability in terms of data acquisition and analysis. Hardware and software considerations are discussed when implementing standardised protocols across multi-vendor platforms together with methods for quality assurance and quality control. Processes of data collection, archiving, curation, analysis, central reading and handling incidental findings are considered in the conduct of multicentre trials. Data protection and good clinical practice are essential prerequisites. Developing international consensus of procedures is critical to successful validation if ADC is to become a useful biomarker in oncology.Key Points: • Standardised acquisition/analysis allows quantification of imaging biomarkers in multicentre trials. • Establishing "precision" of the measurement in the multicentre context is essential. • A repository with traceable data of known provenance promotes further research. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|